Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents
- To determine the rate of engraftment of pediatric FMS-Like Tyrosine Kinase-3
(FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) samples in NOD
scid gamma (NSG) mice.
- To determine the efficacy of treatment of FLT3-ITD xenografts with tyrosine kinase
OUTLINE: Human acute myeloid leukemia cells are injected into NSG mice. Mice are then
treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood
and tissue samples are collected biweekly or weekly and analyzed for the presence of human
CD45+ and CD33+ cells by quantitative flow cytometry.
Ratio of human AML cells to murine cells
Sarah K. Tasian, MD
Children's Hospital of Philadelphia
United States: Federal Government